RARE DISEASES A–Z · LETTER N
Niemann-Pick Disease
Niemann-Pick disease is a name shared by two different lysosomal storage problems. Types A and B come from a missing fat-breaking enzyme; type C comes from a failure to move cholesterol inside cells. All are rare, inherited, and — after decades without options — now partly treatable.
By Dr. Mohamed Ibrahim, MD, PhD — Assistant Professor of Medicine, Transplant Nephrology, University of Maryland School of Medicine · Last reviewed: November 2026
Rare Diseases A–Z is part of the MedicalVideos.com education program. It is produced independently of sponsors, and any future sponsorship will be labelled on the hub.
The guide
The basics
In types A and B the missing enzyme is acid sphingomyelinase, so sphingomyelin fat accumulates in the spleen, liver, lungs, and marrow. Type B — the milder end — causes an enlarged spleen and liver, low blood counts, short stature, and progressive lung disease, with the brain largely spared; type A devastates the infant brain and is fatal in early childhood. Type C is a different fault altogether: the cell cannot move cholesterol and fats out of its recycling compartments, and the damage falls on liver and brain. Type C can present at almost any age — with liver disease in infancy, or in childhood and adulthood with clumsiness, slurred speech, swallowing problems, dementia, psychiatric symptoms that are often misdiagnosed for years, seizures, and a distinctive difficulty moving the eyes vertically.
How it works
For types A/B, diagnosis is by enzyme activity in blood, confirmed by genetic testing (SMPD1), with a biomarker tracking burden. Type C is harder: blood biomarkers (oxysterols and related lipids) now screen for it, genetic testing of the NPC1 and NPC2 genes confirms most cases, and skin biopsy studies were the historical route. Because type C mimics psychiatric illness, ataxia, and dementia, it is a classic missed diagnosis — the combination of vertical gaze palsy, clumsiness, and an enlarged spleen or a history of newborn liver disease should trigger testing. Assessment maps liver, spleen, lung function, neurology, swallowing, and cognition, and family testing follows the recessive pattern.
Day to day
Enzyme replacement therapy now exists for ASMD (types A and B spectrum): regular infusions of the missing enzyme improve spleen and liver size, blood counts, growth in children, and lung disease measures — though the enzyme does not reach the brain, so type A's neurology is unchanged. For type C, the substrate-reduction medicine miglustat modestly slows neurological deterioration and is the established specific therapy in many countries; a newer medicine targeting the cellular stress response has recently been approved in some regions, and combination approaches are evolving. Supportive care — swallowing management, physiotherapy, seizure and psychiatric treatment chosen carefully, nutritional support — runs throughout. Early diagnosis matters in both diseases because treatment preserves more function the sooner it starts.
When to get help
Follow-up is at a metabolic or lysosomal-disease centre, tracking lungs and liver for ASMD and neurological function for type C. Report worsening breathlessness, new swallowing difficulty or choking, falls, or cognitive change. In type C, psychiatric symptoms should always be interpreted with the diagnosis in mind — teams should be told, since some psychiatric medicines worsen movement problems. Vaccinations and prompt infection treatment protect vulnerable lungs. Genetic counselling covers carrier testing for siblings and reproductive options. Support organisations for these ultra-rare conditions are an essential source of practical knowledge for families and clinicians alike.
Common questions
What is the difference between types A, B, and C?
Types A and B are one spectrum from acid sphingomyelinase deficiency (ASMD): type A is the severe infantile brain form, type B mainly affects lungs, liver, and spleen, and intermediate forms exist. Type C is a completely different defect — cholesterol transport within cells — despite the shared name.
Why do doctors check eye movements?
The vertical gaze palsy — difficulty moving the eyes up and down voluntarily while reflex eye movements remain — is so characteristic that it is often the clue that redirects a psychiatric or dementia work-up toward Niemann-Pick type C. Eye movement examination is a standard part of assessing it.
Does enzyme therapy help all types?
Enzyme replacement treats ASMD (types A/B spectrum) — it improves lung, liver, and spleen disease but does not cross into the brain, so it does not change type A neurology. Type C is treated with a substrate-reducing medicine (miglustat) that modestly slows neurological progression, plus symptom care.
How is it inherited?
Both A/B (ASMD) and C are recessive: parents are healthy carriers and each child has a 1-in-4 chance of being affected. Carrier testing and prenatal diagnosis are available, and the conditions are more frequent in some populations — ASMD in Ashkenazi Jewish families, type C in certain founder populations.
More in Letter N
Related
Sources
- Niemann-Pick Disease — MedlinePlus Genetics (MedlinePlus)
- Niemann-Pick Disease (National Organization for Rare Disorders (NORD))
- Niemann-Pick Disease Type C — Genetic and Rare Diseases Information Center (NIH GARD)
This guide is general information, not medical advice. Rare diseases are individual — diagnosis and treatment depend on your own results, other conditions, and treatment history, and are set by your treating team. Never start, stop, or change a medicine because of something you read here. If you have severe breathlessness, uncontrolled bleeding, confusion, sudden weakness, or thoughts of harming yourself, seek urgent care. Enzyme and substrate therapy eligibility depend on type; follow your metabolic centre's plan.